News | CT Angiography (CTA) | August 21, 2015

Loyola University Medical Center First in Illinois to Implement FFR-CT

CT scans can determine blood flow through diseased coronary arteries to determine if a stent is needed

FFR-CT

An example of a FFR-CT study showing a 3-D reconstruction of the coronary tree and a color overlay of virtual FFR readings, including a severe blockage in need of revascularization in the left anterior decending artery. 

August 21, 2015 — Loyola University Medical Center is the first and only hospital in Illinois to offer a new, noninvasive technology to test for coronary artery disease.

The technology employs noninvasive CT scans to calculate how much blood is flowing through diseased coronary arteries that have narrowed due to a buildup of plaque. The patient does not need to undergo an invasive angiogram that involves threading a catheter to the heart.

The test, developed by HeartFlow Inc., has been approved by the U.S. Food and Drug Administration. It’s called fractional flow reserve-computed tomography (FFR-CT).

“FFRCT provides superior patient care and helps guide treatment strategies with a single, non-invasive study that is low risk and provides accurate information,” said cardiologist Mark Rabbat, M.D., FSCCT, an assistant professor in the departments of Medicine and Radiology of Loyola University Chicago Stritch School of Medicine.

Rabbat said FFR-CT can answer important clinical questions such as whether a patient has coronary artery disease. It can determine whether plaque in a coronary artery is restricting blood flow, thereby helping determine whether a patient would benefit from stents or bypass surgery.

More than 16 million adults in the United States have coronary artery disease. The condition occurs when a buildup of plaque narrows arteries that supply oxygen-rich blood to heart muscle. Reduced blood flow to heart muscles can cause angina (chest pain) and shortness of breath. If an artery becomes completely blocked, a patient can suffer a heart attack.

Blockages that reduce blood flow by a small amount can be treated with medical therapy such as cholesterol-lowering drugs or aspirin. But if there is a major reduction in blood flow, the patient may require a stent or bypass surgery.

Until now, the standard test for measuring FFR involved an invasive angiogram and use of an FFR catheter. 

If blood flow is reduced, the blood pressure downstream from the blockage also will be reduced. If this blood pressure is less than 80 percent of the blood pressure in the aorta, a cardiologist may recommend a stent or bypass surgery.

The new FFR-CT technique is noninvasive. CT scans create a digital 3-D model of the arteries leading to the heart. Powerful computer models then simulate the blood flow within those arteries to assess whether blood flow has been restricted by any narrowings. A color-coded map helps physicians determine, vessel by vessel, if sufficient blood is flowing to the heart.

“FFR-CT is a game changer,” Rabbat said. “For the first time, we have a single comprehensive, non-invasive diagnostic test that offers both an anatomic assessment and the functional significance of coronary artery disease. We’re proud to be the first hospital in Illinois to offer this revolutionary technology to our patients.”

For more information: www.loyolamedicine.org

Related Content

The Acist Navvus II Rapid Exchange FFR MicroCatheter delivers even more flexibility and a streamlined crossing profile to assess complicated lesions.

The Acist Navvus II Rapid Exchange FFR MicroCatheter delivers even more flexibility and a streamlined crossing profile to assess complicated lesions.

News | FFR Technologies | July 09, 2020
July 9, 2020 – Acist Medical Systems Inc., a Bracco Group Company, announced the global launch of its Acist Navvus II
The Medis QFR technology allows non-invasive functional FFR assessment of coronary flow based on standard X-ray angiographic images in the cath lab without the use of a pressure wire.

The Medis QFR technology allows non-invasive functional FFR assessment of coronary flow based on standard X-ray angiographic images in the cath lab without the use of a pressure wire.

Feature | FFR Technologies | July 07, 2020 | Dave Fornell, Editor
An OCT intracoronary image showing instent restenosis. The white spots in the vessel wall casting shadows are the stent struts. OCT image data might be used in the future to assess FFR to determine the severity of lesions and determine if they need to be stented.

An OCT intracoronary image showing instent restenosis. The white spots in the vessel wall casting shadows are the stent struts. OCT image data might be used in the future to assess FFR to determine the severity of lesions and determine if they need to be stented.

News | FFR Technologies | May 15, 2020
May 15, 2020 – A late-breaking study aimed to evaluate whether...
In June 2019, Medis received clearance from the U.S. Food and Drug Administration for its QAngio XA 3D technology (QFR). The FFR-angio technology can show the FFR readings in a 3-D image and overlaid on a fluoro image.

In June 2019, Medis received clearance from the U.S. Food and Drug Administration for its QAngio XA 3D technology (QFR). The FFR-angio technology can show the FFR readings in a 3-D image and overlaid on a fluoro image. 

Feature | FFR Technologies | August 05, 2019 | Dave Fornell and Greg Freiherr
New technologies have been developed that may replace the traditional pressure wires and adenosine to assess the...
First Prospective Registry Confirms FFR Impacts CAD Treatment Plans
News | FFR Technologies | June 17, 2019
A prospective, multicenter, multinational study examines how fractional flow reserve (FFR) can impact treatment plans...
One in Four Patients Have Residual Ischemia Following PCI
News | FFR Technologies | March 20, 2019
At the American College of Cardiology’s (ACC) annual meeting, March 16-18 in New Orleans, Philips announced the results...
HeartFlow Analysis Successfully Stratifies Heart Disease Patients at One Year
News | FFR Technologies | March 19, 2019
Late-breaking results confirm the HeartFlow FFRct (fractional flow reserve computed tomography) Analysis enables...
Abbott's Resting Full-cycle Ratio (RFR) intravascular diagnostic test is a newer type of fractional flow reserve (FFR) physiologic assessment. RFR is used to help identify significant narrowings of coronary arteries to determine the need for a stent or if a patient can be treated medically. Abbott FFR.

Abbott's Resting Full-cycle Ratio (RFR) intravascular diagnostic test is a newer type of fractional flow reserve (FFR) physiologic assessment. RFR is used to help identify significant narrowings of coronary arteries to determine the need for a stent or if a patient can be treated medically. 

Technology | FFR Technologies | March 06, 2019
March 5, 2019 –  The U.S.
CathWorks FFRangio System Receives U.S. FDA Clearance
Technology | FFR Technologies | December 21, 2018
CathWorks announced that its FFRangio System received U.S. Food  and Drug Administration (FDA) 510(k) clearance. The...